Highlighted text has been updated as of October 22, 2024. The RELAX-AHF-2 trial failed to show that serelaxin was superior to placebo at improving outcomes in acute heart failure. Patients were ...
TX45 is an Fc-relaxin fusion molecule targeting the RXFP1 receptor, offering potential therapeutic benefits for hypertension and heart failure with preserved ejection fraction (HFpEF). Tectonic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback